A committee on opportunistic infections in patients with haemophilia in the US met to exchange information about the cases and to conduct surveillance. At its second meeting in Washington DC it was agreed that the possibility must be explored and that techniques should be developed immediately to reduce or eliminate the risk of infection from Factor 8 concentrates. Read more about A committee on opportunistic infections in patients with haemophilia in the US met to exchange information about the cases and to conduct surveillance. At its second meeting in Washington DC it was agreed that the possibility must be explored and that techniques should be developed immediately to reduce or eliminate the risk of infection from Factor 8 concentrates.
The Krever Report recorded that "In the autumn of 1983 and early 1984, U.S. fractionators added warnings about the risk of AIDS to the information in the product inserts - Armour, for its factor VIII concentrate, in October 1983; Cutter, for its commercial factor VIII concentrate, in January 1984; and Hyland, for its factor VIII concentrate, in March 1984." Read more about The Krever Report recorded that "In the autumn of 1983 and early 1984, U.S. fractionators added warnings about the risk of AIDS to the information in the product inserts - Armour, for its factor VIII concentrate, in October 1983; Cutter, for its commercial factor VIII concentrate, in January 1984; and Hyland, for its factor VIII concentrate, in March 1984."
The Krever Report notes that by March 1982, 257 cases of PCP or Kaposi's sarcoma (including 25 of both) had been linked to immunosuppression (demonstrated by a reversal of the usual T-helper/suppressor ratio) and identified to the CDC task force. Read more about The Krever Report notes that by March 1982, 257 cases of PCP or Kaposi's sarcoma (including 25 of both) had been linked to immunosuppression (demonstrated by a reversal of the usual T-helper/suppressor ratio) and identified to the CDC task force.
Dr Cooper stated stated that "Source plasma collected outside the U.S. and shipped to overseas consignees manufacturing products not licensed by us are not subject to any U.S. regulations." Read more about Dr Cooper stated stated that "Source plasma collected outside the U.S. and shipped to overseas consignees manufacturing products not licensed by us are not subject to any U.S. regulations."
Dr Cooper indicated that he would be interested in the views of Dr Yellowlees both on the labelling of the products and the "benefit-to-risk considerations". Read more about Dr Cooper indicated that he would be interested in the views of Dr Yellowlees both on the labelling of the products and the "benefit-to-risk considerations".
A letter sent by the US Assistant Secretary for Health to the UK Chief Medical Officer, confirmed that "Source plasma used in manufacturing licensed plasma derivatives, in the US or overseas, must be collected in facilities with US licenses." Read more about A letter sent by the US Assistant Secretary for Health to the UK Chief Medical Officer, confirmed that "Source plasma used in manufacturing licensed plasma derivatives, in the US or overseas, must be collected in facilities with US licenses."
The WHO Resolution urged Member States to promote national self-sufficiency on the basis of voluntary donations and to "enact effective legislation governing the operation of blood services and to take other actions necessary to protect and promote the health of blood donors and of recipients of blood and blood products." Read more about The WHO Resolution urged Member States to promote national self-sufficiency on the basis of voluntary donations and to "enact effective legislation governing the operation of blood services and to take other actions necessary to protect and promote the health of blood donors and of recipients of blood and blood products."
At an NIBSC meeting the National Hemophilia Foundation's position that products should be automatically recalled where a donor was diagnosed with AIDS or characteristics strongly suggestive of AIDS was explained. Read more about At an NIBSC meeting the National Hemophilia Foundation's position that products should be automatically recalled where a donor was diagnosed with AIDS or characteristics strongly suggestive of AIDS was explained.
A meeting was held at the National Institute for Biological Standards and Control ("NIBSC") between civil servants, American and British fractionators, clinicians and scientists. Among the issues discussed was the size of donor pools. Read more about A meeting was held at the National Institute for Biological Standards and Control ("NIBSC") between civil servants, American and British fractionators, clinicians and scientists. Among the issues discussed was the size of donor pools.
There was a single centre in Belize, which was also licensed for fractionation (and hence should have been inspected) by the FDA. Read more about There was a single centre in Belize, which was also licensed for fractionation (and hence should have been inspected) by the FDA.